U.S. International Trade Commission Receives New Complaint
Estimated reading time: 1–7 minutes
The U.S. International Trade Commission (USITC) has received a new complaint. This complaint is about systems, devices, software, chemicals, and supplies used to study proteins. The complaint is filed by Seer, Inc. and The Brigham and Women’s Hospital, Inc.
The USITC is asking for comments from the public. They want to know if the complaint would affect the public interest. This includes public health and welfare, the U.S. economy, and consumers.
The complaint is against Nanomics Biotechnology Co., Ltd. of China. The complaint says they violated section 337 of the Tariff Act of 1930. They want the USITC to stop some imports and sales of these products.
The USITC is also interested in knowing how these products are used in the U.S. They want to know if any similar products are made in the U.S. and if they can replace these items.
The USITC will accept comments for eight days after the notice is published in the Federal Register. They will also allow further comments if a decision is made.
The USITC wants all comments to be five pages or less. They must be sent electronically through the USITC’s Electronic Document Information System.
The USITC will accept no paper filings. Anyone with questions can contact Lisa R. Barton, Secretary to the Commission.
If anyone wants their document to be confidential, they must ask the Commission for confidential treatment.
This news is important because it affects imports, businesses, and possibly the economy. The USITC uses section 337 of the Tariff Act to handle these cases.
This notice is a reminder of how trade laws protect U.S. interests.
For more information, visit the USITC’s website or contact their office.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
